The MosaiQ AiPlex CD is designed to improve the  accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows EYSINS, Switzerland , Feb.

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

Acrivon Therapeutics, Inc. (ACRV) is up by 14 percent on Wednesday. The stock surged after the company announced that the U.S. Food ...

The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...

The following is a summary of “NTHi killing activity is reduced in COPD patients and is associated with a differential ...

The test, which runs on the Swiss company's high-throughput MosaiQ System, detects 15 different autoantibodies.

AliveDx’s CE mark for the systematic autoimmune rheumatic disease (SARD) assay marks its fifth approval in the past 18 months ...

Tests broaden access to accurate, easy-to-use diagnostics for patients in a decentralised setting Roche has been granted US ...

Glo Fiber's future-proof, reliable high-speed internet service... at 05:00 AliveDx Expands Autoimmune Menu with IVDR-CE Marked MosaiQ AiPlex® CTDplus Multiplex Assay to Aid in Diagnosing Systemic ...

The global lateral flow assay (LFA) market, valued at USD 4.3 billion in 2023, is projected to grow steadily at a CAGR of 4.7 ...

The prevalence and prognostic significance of KRAS G12C mutation in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract ...